MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
MAIA Biotechnology Stock Up 4.1 %
Shares of MAIA stock traded up $0.08 during mid-day trading on Friday, hitting $2.04. 121,542 shares of the company's stock were exchanged, compared to its average volume of 234,990. MAIA Biotechnology has a fifty-two week low of $1.40 and a fifty-two week high of $5.99. The stock has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $2.13. The stock has a market cap of $53.37 million, a price-to-earnings ratio of -1.48 and a beta of 0.20.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Further Reading
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
